Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For patients with BRAF mutations, combinations of BRAF and MEK inhibitors demonstrated respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Capone, Mariaelena, Grimaldi, Antonio M., Mallardo, Domenico, Simeone, Ester, Madonna, Gabriele, Roder, Heinrich, Meyer, Krista, Asmellash, Senait, Oliveira, Carlos, Roder, Joanna, Grigorieva, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440152/
https://www.ncbi.nlm.nih.gov/pubmed/30925943
http://dx.doi.org/10.1186/s40425-019-0569-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440152/
https://www.ncbi.nlm.nih.gov/pubmed/30925943
http://dx.doi.org/10.1186/s40425-019-0569-1

Ejemplares similares